Carmot Therapeutics
Carmot Therapeutics is a biotech company focused on developing innovative therapies for obesity and diabetes. They are conducting multiple clinical trials for their pipeline of GLP-1/GIP receptor agonists, aiming to provide effective treatments with minimal side effects. Their mission is to answer some of the biggest questions in healthcare through advanced research and development.
Industries
Nr. of Employees
small (1-50)
Carmot Therapeutics
Patents
Products
GLP-1/GIP dual receptor agonist — once-weekly subcutaneous (clinical-stage)
A once-weekly subcutaneous dual GLP-1/GIP receptor agonist developed with biased signaling properties to minimize beta-arrestin recruitment and reduce receptor desensitization; in clinical development for obesity and type 2 diabetes.
GLP-1/GIP receptor agonist — clinical-stage (Phase 2 study in overweight/obesity and T1D)
A GLP-1/GIP receptor agonist in multi-center randomized placebo-controlled Phase 2 clinical development to assess efficacy, safety, tolerability, and pharmacokinetics in participants with overweight/obesity and type 1 diabetes.
Oral small-molecule GLP-1 receptor agonist — clinical-stage (Phase 1)
A once-daily orally administered small-molecule GLP-1 receptor agonist designed as a biased agonist to activate cAMP signaling with minimal beta-arrestin recruitment; in Phase 1 clinical trials to assess safety, tolerability, PK and PD in participants with overweight/obesity and type 2 diabetes.
GLP-1/GIP dual receptor agonist — once-weekly subcutaneous (clinical-stage)
A once-weekly subcutaneous dual GLP-1/GIP receptor agonist developed with biased signaling properties to minimize beta-arrestin recruitment and reduce receptor desensitization; in clinical development for obesity and type 2 diabetes.
GLP-1/GIP receptor agonist — clinical-stage (Phase 2 study in overweight/obesity and T1D)
A GLP-1/GIP receptor agonist in multi-center randomized placebo-controlled Phase 2 clinical development to assess efficacy, safety, tolerability, and pharmacokinetics in participants with overweight/obesity and type 1 diabetes.
Oral small-molecule GLP-1 receptor agonist — clinical-stage (Phase 1)
A once-daily orally administered small-molecule GLP-1 receptor agonist designed as a biased agonist to activate cAMP signaling with minimal beta-arrestin recruitment; in Phase 1 clinical trials to assess safety, tolerability, PK and PD in participants with overweight/obesity and type 2 diabetes.
Expertise Areas
- Clinical trial management
- Clinical pharmacology and PK/PD
- Obesity and diabetes therapeutic development
- Biased agonist medicinal chemistry
Key Technologies
- GLP-1 receptor agonism
- GLP-1/GIP dual receptor agonism
- Biased agonism (beta-arrestin signaling modulation)
- Oral small-molecule therapeutics